Abstract

Acetylcholinesterase (ACHE) is an enzyme. Its main extracellular function isto hydrolyze the Acetylcholine to choline and acetate,and maintain the correct levels of Acetylcholine in the body and according to the Environmental Factors. Another function for (ACHE) in intra cellular compartment is to stimulate cell proliferation and apoptosis. In this study, we try to investigate the (ACHE) and prostate cancer overlapping to get new diagnostic markerand/or treatment for prostate cancer. Results: There is no significant difference in serum (ACHE) of patients with prostate cancer (12.90 ± 4.17ng /ml), in comparison to control group (9.0 ± 1.78 ng /ml),(p>0.05). But there is significant increase in serum (ACHE) incases with high grade prostate cancer with Gleason grade more than 7,(11.90 ± 2.11ng /ml),in comparison to lower grade prostate cancerwith Gleason grade less than 7, and control group (10.20 ± 2.20and 9.0 ± 1.78ng /ml respectively),(p<0.05). Conclusion: Because of thevariation inthe level of serum (ACHE) in patients with prostate cancer, this marker can't consider as prognostic protein for diagnosis ofprostate cancer. However further prospective studies are recommended to demonstrate its role in the diagnosis, grading and elimination of the tumor.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call